DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Mayo clinic tests faster radiation for devastating childhood brain tumor
Disease control Recruiting nowThis study is testing a new way to deliver radiation therapy for a serious type of brain tumor called diffuse midline glioma. Instead of the standard 6-week treatment, patients receive a shorter, 2-week course. The main goal is to see if this shorter schedule is as effective at c…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 01, 2026 23:20 UTC
-
Scientists use sound waves to unlock brain barrier for child cancer treatment
Disease control Recruiting nowThis early-stage study is testing whether a non-invasive focused ultrasound device can safely and temporarily open the protective blood-brain barrier in children with progressive diffuse midline glioma, a severe brain tumor. The goal is to allow more of an oral chemotherapy drug …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Race for a better treatment for devastating childhood brain cancer
Disease control Recruiting nowThis large, international Phase 3 trial aims to find a better treatment for diffuse intrinsic pontine glioma (DIPG), a rare and aggressive brain tumor with very few options. It will compare two drugs, ONC201 and everolimus, in over 430 patients, including children and adults, to …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for kids with devastating brain tumors: trial tests flexible drug combinations
Disease control Recruiting nowThis trial is testing new drug combinations for children and young adults with aggressive brain tumors called diffuse midline gliomas (DMGs), which currently have very few treatment options. It uses a flexible 'platform' design to test different drug combinations, including ONC20…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for kids with deadly brain tumors: trial matches treatment to tumor genetics
Disease control Recruiting nowThis study aims to find better treatments for children and young adults newly diagnosed with aggressive brain tumors. Researchers will analyze the genetic makeup of each patient's tumor to match them with a targeted therapy that might work best for their specific cancer. The goal…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New pill tested for Tough-to-Treat brain cancers
Disease control Recruiting nowThis is the first study in people testing an experimental pill called ONC206 for adults with recurrent brain tumors that have few treatment options. The main goal is to find the highest safe dose and understand the side effects. Researchers will enroll about 102 patients to test …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for kids with devastating brain cancer: First-in-Human vaccine trial begins
Disease control Recruiting nowThis is a first-in-human safety study testing a new, 'off-the-shelf' cancer vaccine combined with two immunotherapy drugs for children with DIPG and DMG, aggressive brain tumors with very few treatment options. The trial aims to see if this combination is safe and tolerable for c…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope for kids with devastating brain cancer: trial tests Life-Extending drug combos
Disease control Recruiting nowThis study is testing two different drug combinations to see if they can help children and young adults with aggressive brain tumors live longer. The trial is for patients who have just finished radiation therapy. One group receives two drugs (ribociclib and everolimus), while an…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
First human trial launches for 'KIND t Cells' targeting deadly childhood brain cancer
Disease control Recruiting nowThis is a first-in-human safety study for a new cell therapy called KIND T cells. It is for children and young adults (ages 2-25) with a specific, hard-to-treat brain tumor called H3.3K27M-mutated diffuse midline glioma. Doctors take a patient's own immune cells, genetically modi…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New hope for kids with aggressive brain tumors: pioneering therapy delivered directly to the brain
Disease control Recruiting nowThis early-stage study is testing a new type of personalized immune therapy called B7-H3-CAR T cells for children and young adults (up to age 21) with brain tumors that have come back or haven't responded to standard treatments. The therapy involves collecting a patient's own imm…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
Major european study aims to crack the code on brain tumor treatment
Knowledge-focused Recruiting nowThis study is collecting information on people with various types of brain tumors to see if a new, more detailed way of classifying them helps doctors choose better treatments and predict outcomes more accurately. It will follow about 1,650 patients for up to five years to compar…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:15 UTC
-
Global effort launched to crack the code of devastating childhood brain cancer
Knowledge-focused Recruiting nowThis study is creating a worldwide database and tissue bank for patients diagnosed with DIPG or DMG, which are rare and aggressive brain tumors primarily affecting children. Researchers are collecting medical records, scans, and tumor samples from up to 1,500 patients to better u…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Mar 17, 2026 13:09 UTC